Aju IB Investment Co., Ltd., a venture capital and private equity subsidiary of AJU Corporation Co., Ltd., was established in 1974, initially operating as Kibo Technology Advancing Capital Co. Headquartered in Seoul, South Korea, with an additional office in Boston, Massachusetts, the firm is active in mezzanine financing, buyouts, corporate restructuring, and all stages of venture investments. Its primary focus is on small to medium-sized startup enterprises, predominantly in South Korea, though it also pursues international opportunities. For venture capital, it targets high-technology sectors, while private equity investments typically center on manufacturing. The firm's investment scope is broad, spanning information technology, including mobile service platforms, software, semiconductors, and digital content, as well as biotechnology, life sciences, and environmental solutions. It also delves into advanced information communication technologies such as the Internet of Things, artificial intelligence, smart car developments, and advanced materials. Specific medical areas of interest include companies developing immune system platform technology, oncology drugs, and ophthalmic pharmaceuticals. In South Korea, Aju IB Investment prioritizes companies that have achieved a rating of T5 or higher from technology credit bureaus. The Boston office maintains a specialized mandate, concentrating on therapeutics addressing significant unmet medical needs, enabling platform technologies with maturing lead candidates, potential partnerships with Korean pharmaceutical companies, and investments in medical devices and diagnostics. Financially, the firm generally invests between $0.87 million and $2.61 million for venture capital opportunities and between $4.36 million and $17.45 million for private equity transactions. Exit strategies commonly involve initial public offerings (IPOs) or mergers and acquisitions.